Електронен магазин за натурални хранителни добавки и продукти
Телефон за поръчки: 02 818 48 70

Коксамин / COXAMIN

  • 17.5000 BGN
    17,50 лв.
  • Харесвания: 5.0 от 5
    Мнения: 1
  • Наличност: На склад

Тип продукт:  Таблети
Производител:  MARIGOT LTD - Ирландия
Брой:  60 бр. таблети
Категория : Хранителни добавки
Коксамин / COXAMIN

Натурален биоактивен калций, произведен от червени водорасли. 100% растителен продукт.

Описание

Вземи своя ПОДАРЪК от COXAMIN сега!


Всяка опаковка от серията Подробно

Състав

  Пълен състав на микроелементи и минерали в COXAMIN   ...

Подробно

Прием

1 до 2 таблети дневно след храна.

Подробно

Заболявания

- при остеопороза (изгражда по-здрава костна структура и забавя костната загуба след менопауза);- при намалена ставна подвижност (спомага за укрепване на ставните повърхности и подобрява с...

Подробно

Изследвания

Прочетете повече, изтеглете PDF файл с  изследванията на Coxamin - натуралният калций от природата.

Подробно

Сертификати

Подробно

Описание

Вземи своя ПОДАРЪК от COXAMIN сега!


Всяка опаковка от серията COXAMIN съдържа талон, който Ви дава възможност да получите една безплатна опаковка COXAMIN по Ваш избор.
Изрежете баркодовете на три опаковки COXAMIN и ги залепете на талона. Попълнете данните, както е отбелязано на талона и така попълнения талон представете в най-близката до Вас аптеката. Срещу него ще получите безплатната опаковка от сериата COXAMIN по Ваш избор.

Всеки талон Ви дава възможност да намалите цената на Вашето лечение!

Ако фармацевта или вие имате въпроси относно промоцията, на талона са описани всички начини да се свържете с нас.

Търсете талоните във всяка опаковка или при вашия лекар!

----

Coxamin e уникален продукт, съдържащ калций, изцяло на растителна основа. Произвежда се от калцифицирани Червени водорасли - Lithothamnion Calcareum. Те обитават ограничени територии около чистите брегове на Югозападна Ирландия и Западна Исландия. Жизненият цикъл на водораслите е четири-пет години. За този относително кратък период те усвояват голямо количество минерали от морето.

Coxamin има уникална пореста структура, подобна на пчелна пита, която след първична хидратация се видоизменя в гладка. Тя не наподобява тебеширената, зърнеста структура, с която обикновено свързваме представата за калциев продукт.
 

Coxamin e най-добре усвоимият калциев продукт. Калцият, получен от Lithothamnion Calcareum, е с 20% по-ефективно усвоим от калция в млечните продукти и с малко над 40 % от трикалциевия фосфат.  

Добрата усвояемост на Coxamin, се дължи на специфичната му структура:
В Coxamin, съдържанието се поделя между три полиморфни форми - калцит, арaгонит (орто-ромбична структура), ватерит (шестоъгълна структура). Калциевият карбонат например се състои почти изцяло от калцит – ромбоидна решетъчна форма 

Coxamin не е просто калций. В него се съдържат още магнезий (2,5%), бор, мед, манган, селен, цинк и много други микроелементи и минерали (общо 74 на брой). Магнезиевият минимум е нужен за добрата абсорбация на калция от организма, а борът и цинкът играят важна роля за биовиталността на калциевия източник.

Coxamin е уникален, различен от всички източници на калций с формула, свободна от лактоза и фосфати.  Не съдържа пестициди, консерванти и оцветители.

Изцяло растителният му произход го прави подходящ за вегетарианци.

Coxamin е произведен от стандартизиран продукт (Lithothamnion Calcareum), притежаващ сертификация за качество от Kosher, Halal, USA FDA „GRAS”, ЕU Health, Non GMO, ISO  и HACCP. 

Наличен в аптечната мрежа.

Състав

 

Пълен състав на микроелементи и минерали в COXAMIN

 

 

 

 Вещество

 

 

 Единица 

 

  Количество за

1000 mg COXAMIN

 

 

 

  Вещество

 

 

 Единица 

 

Количество за

1000 mg COXAMIN


Алуминий

 

ppm

 

123

 

Меркурий

 

ppm

 

0,006

 

Антимон

 

ppm

 

0,43

 

Молибден

 

ppm

 

1,13

 

Арсен

 

ppm

 

0,17

 

Неодим

 

ppm

 

0,042

 

Барий

 

ppm

 

5,73

 

Никел

 

ppm

 

2,21

 

Берилий

 

ppm

 

0,79

 

Ниобий

 

ppm

 

6,68

 

Бисмут

 

ppm

 

0,085

 

Осмий

 

ppm

 

< 0,05

 

Бор

 

ppm

 

14,6

 

Паладий

 

ppm

 

< 0,01

 

Бром

 

ppm

 

10,9

 

Фосфор

 

ppm

 

268

 

Кадмий

 

ppm

 

0,26

 

Платина

 

ppm

 

< 0,01

 

Калций

 

ppm

 

360 100

 

Калий

 

ppm

 

2380

 

Въглерод

 

ppm

 

122 000

 

Празеодим

 

ppm

 

0,45

 

Церий

 

ppm

 

0,84

 

Рений

 

ppm

 

< 0,05

 

Цезий

 

ppm

 

0,76

 

Родий

 

ppm

 

< 0,01

 

Хлорид

 

ppm

 

1070

 

Рубидий

 

ppm

 

1,27

 

Хром

 

ppm

 

1,51

 

Рутений

 

ppm

 

0,085

 

Кобалт

 

ppm

 

1,35

 

Самарий

 

ppm

 

0,052

 

Мед

 

ppm

 

7,88

 

Скандий

 

ppm

 

0,272

 

Диспросий

 

ppm

 

0,084

 

Селен

 

ppm

 

1,28

 

Ербий

 

ppm

 

2,53

 

Силикон

 

ppm

 

920

 

Европий

 

ppm

 

0,048

 

Сребро

 

ppm

 

0,41

 

Флуорид

 

ppm

 

5,29

 

Натрий

 

ppm

 

1930

 

Гадолиний

 

ppm

 

0,18

 

Стронций

 

ppm

 

2560

 

Галий

 

ppm

 

4,06

 

Сяра

 

ppm

 

6380

 

Германий

 

ppm

 

0,17

 

Тантал

 

ppm

 

0,055

 

Злато

 

ppm

 

< 0,01

 

Телур

 

ppm

 

0,038

 

Хафний

 

ppm

 

< 0,03

 

Тербий

 

ppm

 

0,042

 

Холмий

 

ppm

 

< 0,05

 

Талий

 

ppm

 

0,72

 

Индий

 

ppm

 

0,049

 

Торий

 

ppm

 

0,042

 

Йод

 

ppm

 

27,6

 

Тулий

 

ppm

 

0,113

 

Иридий

 

ppm

 

< 0,05

 

Калай

 

ppm

 

0,075

 

Желязо

 

ppm

 

419

 

Титаний

 

ppm

 

9,03

 

Лантан

 

ppm

 

0,88

 

Волфрам

 

ppm

 

0,087

 

Олово

 

ppm

 

0,115

 

Ванадий

 

ppm

 

7,06

 

Литий

 

ppm

 

2,85

 

Итербий

 

ppm

 

0,081

 

Лутеций

 

ppm

 

0,020

 

Итрий

 

ppm

 

1,19

 

Магнезий

 

ppm

 

22 500

 

Цинк

 

ppm

 

9,34

 

Манган

 

ppm

 

36,6

 

Цирконий

 

ppm

 

2,79

 

 

1 ppm = 1 μg = 0.0001 mg   

Прием

1 до 2 таблети дневно след храна.

Заболявания

- при остеопороза (изгражда по-здрава костна структура и забавя костната загуба след менопауза);
- при намалена ставна подвижност (спомага за укрепване на ставните повърхности и подобрява ставната подвижност);
- за възстановяване след физическа активност (намалява мускулната умора и ускорява възстановяването);
- подобрява състоянието на кожата, косата, ноктите и оказва положително влияние върху нервната и сърдечно-съдовата система;
- набавя необходимите по време на бременност калций, магнезий, желязо и други минерали и микроелементи. (Да се приема след консултация с лекар);
- при всички състояния, изискващи увеличен прием на микро и макроелементите Калций (Ca), Магнезий (Mg), Фосфор (P), Сяра (S), Желязо (Fe), Калий (K), Манган (Mn), Бор (B), Йод (I), Цинк (Zn), Мед (Cu), Селен (Se), Кобалт (Co) и други, които са посочени в таблицата;
- поради растителния си произход продуктът е подходящ за вегетарианци;
- COXAMIN не предизвиква констипация, щади стомашната лигавица и паренхима на бъбреците;

Изследвания

Прочетете повече, изтеглете PDF файл с  изследванията на Coxamin - натуралният калций от природата.

Coxamin при ренална остеодистрофия

Coxamin е препарат особено подходящ при болни с хронична бъбречна недостатъчност за профилактика на костната болест. Препаратът повлиява благоприятно множество от патогенетичните механизми, по които се развива реналната остеодистрофия чрез:

А/ Набавяне на необходимия на организма биоактивен Калций.

Б/ Подтискане на повишената активност на Паратхормона типична за хроничната бъбречна недостатъчност.

В/Алкализиращ ефект на препарата доказан с проучването на Marigot  неутрализиращ повишената киселинност на организма при болни с хронични бъбречни увреждания.

Г/ Липса на фосфати в състава на препарата, които да засилват хиперфосфатемията при бъбречна недостатъчност.

Изброените по-горе свойства в съчетание с много добрата стомашна поносимост и липсата на запичащ ефект типичен за повечето калциеви препарати, прави Coxamin уникален препарат заместващ едновременното прилагане на няколко медикамента за профилактика на реналната остеодистрофия и вторичния хиперпаратиреоидизъм при болни с хронична бъбречна недостатъчност.

Д-р Желев,

МБАЛ Бургас

Отделение по хемодиализа

------------

 

Effect of Calcium-based supplements on bacterial fermentation in the human colon- an in vitro IBS model

Final report from Teemu Rinttila, E. Pennala & J. Apajalahti at Alimetrics

Background

IBS is characterised by a decrease in the presence of certain gut microbiota, such as lactobacilli and bifidobacteria. In addition, groups such as Bacteroidetes and Coriobacteriaceae tend to be higher in healthy subjects.

Alterations in microbial metabolite profiles, for example the skewing of short-chain fatty acids (SCFA) and increased gas production are also associated with IBS.

Methodology

Aquamin and AquaPT were applied at three doses ranging low (close to doses achieved in vivo) through medium to high, which was increased five-fold to yield a super dose. Super-dosing is commonly employed when first testing a product so that, if it turns out no results are seen from the super dose, it will be known that the product is unlikely to be effective.

The digested matter from the ileum and colon of pigs (fed for 7 days on a human diet) was collected. A female volunteer with mixed-type IBS (combination of diarrhoea and constipation events) provided the inoculum to introduce typical IBS-related microbiota to the digesta samples. This mix was allowed to ferment at 37˚C over 22 hours.

Results

Gas Production

Excessive gas production is a problem in IBS. At the highest dose AquaPT  significantly inhibited gas production but Aquamin did not. This would indicate that it is the pine bark or green tea (perhaps in combination with Aquamin) that has the effect.

Short Chain Fatty Acid Production

SCFA production is related to eth level of fermentation in the gut. Again, in this case Aqua PT at the highest dose induced significant decrease in SCFA production, indicating the importance of green tea and pine bark.

In IBS lactic acid exceeds the buffering capacity of the colon, leading to increased discomfort and causing damage to the intestinal lining by erosion of colonic mucosa. Aquamin decreased levels of latic acid, something which may indicate that Aquamin is stimulating the activity of lactate-utilising bacteria.

pH

In a healthy colon pH ranges 5.5-7. In a disturbed state the additional fatty acid production may reduce buffering capacity and lower overall pH. Aquamin and AquaPT significantly raised the pH in a dose-dependent manner. Since both products were effective in this case it appears the buffering activity is not related to green tea or pine bark.

Colon Microbiota

The microbiota population in a healthy person differs to that in an IBS sufferer. Overall, the super doses of Aquamin and AquaPT inhibited microbial growth. Interestingly, although a high dose of Aquamin reduced microbial numbers, it did not affect SCFA or gas production, indicating that Aquamin allowed the bacteria to utilise energy sources and produce metabolites in the absence of growth.

Clostridial Cluster IV is a beneficial microbial group and it was increased even at medium doses of AquaPT. Strains in this group have been shown to have anti-inflammatory properties and, moreover, are found in decreased numbers in IBS patients.

On the contrary, the genus Veillonella, which are considered non-beneficial, were significantly reduced at medium AquaPT and at high Aquamin.

Conclusion

These results are very positive and Teemu is enthusiastic about them. He has suggested some ways in which we can advance to the next step. He is currently putting together proposals which we can read and decide whether or not to proceed. In brief, he would like to repeat the tests after treating the products in a gastric digestion mimicker to compare the effects between that and untreated product. In addition he acknowledged that inoculates should be obtained from other individuals due to the variance found among IBS patients. Finally, it would be necessary to determine the lowest effective dose in between the medium and high range.

------------

Update on FOOD PROJECTS- September 2011


1.       ALIMETRICS, FINLAND

To investigate alterations in intestinal bacterial in an in-vitro IBS model system.  

Details: Alterations in intestinal bacterial in control and 2 different treatment samples (Aquamin & AquaPT - 3 concentrations of each) will be measured by DNA methodology and compared against the ratios of a panel of bacteria known to be present in the normal and IBS gut.

Update: Final report has been received. Please see full and edited versions attached.  In brief the results are positive in showing Aqua PT could beneficially alter gas production, pH, SCFAs and microbiota (it dampened the negative microbes and enhanced the healthy ones). Aquamin was also effective but not as broadly as Aqua PT.


2.       APOPTOSIS – PROF. NORA O’BRIEN, UCC

Ongoing: Results are expected November 2011

Details: The anti-oxidant potential of Pine bark extract (PBE) and Green tea (GT) will be measured in-vitro (FRAP, DPPH). Cytotoxicity and apoptosis in U937 (tumour) and Human peripheral blood mononuclear cells (HPBMC)(normal cells) will be measured and LD50s established.

Update

Preliminary data from Nora’s post-doc, Yvonne O’Callaghan, shows the high total phenol content of green tea extract (GTE) and pine bark extract (PBE), while, as expected, Aquamin has nil.

The antioxidant (glutathione, catalase and superoxide dismutase) and antigenotoxic potential of Aquamin, PBE, GTE will be measured in U937 cells. Initial FRAP testing shows minimal antioxidant activity for Aquamin and excellent activity for GTE and PBE. There is a good possibility that Aquamin has antioxidant effects in cells that will be detected by some of the other methods. Initial toxicity data shows Aquamin to be extremely non-toxic but apoptosis is yet to be examined specifically- this will be done by DNA laddering.

 

ALIMENTARY PHARMABIOTIC CENTRE (APC), UCC


3.       To investigate if Aquamin/AquaPT improves inflammatory biomarkers in subjects with moderate to severe OA and in healthy subjects (Profs. Michael Murphy & Ted Dinan)

Details:  12 healthy subjects will take Aquamin for 6 weeks. 2 groups of 12 subjects with moderate to severe OA will take either Aquamin or AquaPT for 6 weeks.  WOMAC scores and inflammatory markers (NFkB, COX2, TNFα, IL-1β, IL-6) are to be measured at the beginning and end of the study.

Update: All normal subjects have completed and half of the OA subjects are now on the feeding trial. The plan to enhance recruitment through use of GPs was not successful due to poor feedback from the GPs themselves. Two adverts were placed in the Cork Independent and two more will appear in the Cork news. Natural and alternative practitioners will be contacted as this will increase communication with individuals looking for non-pharmaceutical interventions.   

4. A randomised, double-blind, placebo-controlled study to determine if Aquamin improves digestive discomfort in healthy subjects (Profs Eamonn Quigley & Ted Dinan)

Details: A total of 60 subjects (3 groups) that are ROME 3 negative (the criteria for diagnosing IBS) but suffer from regular digestive discomfort will be randomised to receive either placebo, Aquamin or AquaPT for 6 weeks. Digestive discomfort is defined as experiencing occasional (1-3 times/week) bloating, flatulence or stomach discomfort. Uric acid, IL-6 and IL-8, and non-fasting cholesterol levels have also been included in the protocol.

Update: The digestive discomfort trial is still on track to be completed by Christmas and feedback to the trial nurse (who is blinded) is very positive.

PROF. FERGAL O’BRIEN, ROYAL COLLEGE OF SURGEONS, DUBLIN


5.       Collagen Scaffolds

Update: The Aquamin scaffolds have now been completed and have successfully incorporated Aquamin F.  Having conducted analysis, they found that the Aquamin-infused scaffolds maintain a good porosity, which is desirable for allowing infiltration of cells. The post-doc on this project, Orlaith Brennan, is currently applying cell solutions to the scaffolds. They are hopeful for good results here as they predict a very interesting publication to come from it.

OVX rat study

Details:

The 4 groups to be tested are:

  1. Control (Sham)
  2. OVX Control (including a calcium control)
  3. OVX + Aquamin (does Aquamin prevent degeneration of bone?)
  4. OVX + Aquamin (delayed treatment)- (Does Aquamin actively repair bone?)

The tibia, femur and spine of each animal will be analysed by Micro CT and mineralisation microscopy (backscatter SEM) at 0, 2, 4, 8 12 and 18 weeks. We will also take blood samples for biomarker analysis.

Update: The ovariectomised rats are arriving to the lab in Trinity College on 29/09/2011. Once they are settled Orlaith will begin the feeding trial. All samples will be analysed towards the end of the project so results can be expected early (March) 2012.

PROF. JIM VARANI, DEPT OF PATHOLOGY, UNIVERSITY OF MICHIGAN

Project: New 15 month mouse trial with intermediate time points (0, 5, 12, 18 months).

Update: 360 mice were used in this repeat study and time points were taken at 6 weeks (control), 5 months, 12 months and 18 months. The previous pilot study from Jim Varani only looked at a single time point at 15 months with 20 mice/group. 

6.    Polyp study: These data are excellent and echo the original publication in Integrative Cancer Therapies. Polyp formation in the animals fed the HFWD was 25.7%, polyp formation in animals supplemented with Aquamin was only 4.3%, while in animals supplemented with calcium carbonate alone polyp formation was 12.9%. Thus Aquamin is more effective than calcium alone at comparable calcium levels in preventing polyp formation. Interestingly polyp formation was higher in female mice than in males for unknown reasons. This manuscript is currently 90% complete. Update: This manuscript is ready to go out and will be submitted along with the liver paper (below) imminently. He says that for both cases Aquamin provided significant benefit. He is attending a conference (American Institute for Cancer Research, AICR) in November where he will present two posters describing this work.


7.    New study: The effects of Aquamin on proliferative biomarkers in humans

Ongoing: Jim wishes to begin a new 28 day, 3 arm study (Aquamin vs Calcium control vs placebo) on healthy human volunteers (20 volunteers per group). A lower sigmoid biopsy will be taken at the beginning and end of the study and proliferation biomarkers measured. Jim is applying for funding. The closing date for funding application is 5th October 2011. Update: Jim is using the in vitro polyp data in his application to launch a clinical study investigating polyps in humans. The application went out earlier this week but they will not hear back until February 2012. He intends to talk to people about funding for the clinical trial while at the AICR conference. 

8.   Liver Disease: These data also echo those published in the colon cancer paper by Varani. However, the larger study has provided so much data that they will be presented in a separate manuscript for publication. Similarly to the polyp study, lesions detected in the liver were highest in animals fed the HFWD. The numbers of lesions decreased significantly on supplementation with Aquamin. Calcium alone was not as effective as Aquamin – again suggesting a significant role for the multi-minerals in Aquamin. Interestingly, virtually all the liver lesions were in male mice (reason unknown). Update: As above  

9.   Bone Data: Again the results confirm the bone data previously published. Female mice lost bone mineral and strength on the HFWD and this was prevented by Aquamin. Bone changes (cortical and trabecular) in the HFWD can be seen at the early 5 month time point as can protection from Aquamin. Write up on these results is due to start within the next few weeks. Update: write-up underway 

10.  Skin Data: Dermatitis usually develops on mice kept for long periods of time. The dermatitis is usually manageable unless it ulcerates when it can lead to infection and death. Animals supplemented with Aquamin developed dermatitis at the same rate as the other groups however there was a much lower rate of ulceration. Update: Analysis of data is being finalized and a manuscript is being composed. Jim will send on findings as soon as analysis is complete.

 

PROF. PADRAIC FALLON, INSTITUTE OF MOLECULAR MEDICINE, TRINITY COLLEGE DUBLIN  

11.   Details: Aquamin supplementation in mice with spontaneous colitis (mild-moderate and moderate-severe strains). No adverse effects were seen over the 25 week intervention period and preliminary data suggests that Aquamin can ameliorate the development of colitis in certain mouse strains.

Update: Padraic’s lab manager has left so his workload has unexpectedly increased. He plans to complete the paper by November.

PROF. DAN BARRY, UNIVERSITY OF COLORADO, USA  

12.   BMD and calcium supplementation in competitive male cyclists – 1 year study.

Details: The effects of timing on calcium supplementation (1000mg as chews + Vit D) relative to exercise (supplementation either 30 mins before or 1 hour after exercise) on changes in BMD over the course of a year of training and competition is being measured. This study will also measure bone markers such as CTX and PTH. The study began in Q1 2009

Update: Dan no longer works at this institute but is in regular contact with the post-doc in charge. So far, an analysis of calcium before vs. after exercise in cyclists has been finished and begun working on 2 manuscripts. Dan will access these results and inform us shortly.

  13.   The effect of calcium on Menopausal Women during exercise

This study is similar to the published study on cyclists. Post-menopausal women walked for 60 minutes on a treadmill at 80% VO2max. Either 1000mg Calcium (Aquamin soluble) (taken at start or 1 hour before) or placebo was taken prior to exercising. Changes in PTH, CTX, and Ca levels were measured.

Update: A colleague of Dan’s will be taking over this study in October.

PROF. IAN ROWLAND, UNIVERSITY OF READING & DR. CHRIS GILL, COLERAINE  

14.   Project: Faecal Water Study

Details: This study is investigating if Aquacal supplementation reduces the cytotoxicity of faecal water as measured by in-vitro methods. This is a 20 subject, placebo-controlled, 2 week, parallel–group study. 

Update: The analysis has been completed and the results sent for unblinding and interpretation to the University of Reading. Chris has reported a slight delay with this and is tending to it now.

 EU FUNDED PROJECTS  

15.   SWAFAX – Universities of Ulster & Reading & Cybercolloids

Ongoing: This project has been funded by the EU under framework 7 and is being run with the same partners as HYFFI. The object is to characterise polyphenol rich isolates from seaweed (Asco) both in-vitro and in-vivo for eventually combination with Aquamin. This project will end October 2012.

Update: The food grade polyphenols extract for the in vivo studies has been produced, characterised, encapsulated and delivered to UoR and UU. The bioavailability study has started and ethics have been approved for the long term study. The large scale human intervention study is underway.

O'Gorman et al Phyto Res 2011

Сертификати

Коментари

Мнения

Много доволен от Жоро
Оценка
Определено тонусът ми е много добър. Чувствам се много добре и ще се радвамд а комбинирам с Коксамин с някоя друга хранителна добавка.

Как ще оцените този продукт? *

  1 звезда 2 звезди 3 звезди 4 звезди 5 звезди
Оценка